Search

Displaying results 1181 - 1190 of 10000 in total
  1. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [L44918,L44948] It received a similar approval in the EU in September 2023. … [A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

  2. Indication

    Ulceration of the mouth

    go.drugbank.com/conditions/DBCOND0100372
    Drugs: Apremilast · Benzethonium · Benzocaine · Choline salicylate · Dequalinium · Lidocaine +7 more
    Synonyms: Pain in oral cavity
  3. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    Simoctocog alfa is a fourth-generation BDD FVIII product made in the human embryonic kidney (HEK) cell line. … Full human post-translational modifications via elimination of potentially immunogenic glycosylation patterns found in non-human cell lines led to decreased immunogenicity and longer half-life [A31525]

  4. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    US in December 2021. … Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the

  5. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    [A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … [A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast

  6. Drug

    Prucalopride

    go.drugbank.com/drugs/DB06480
    ApprovedInvestigational

    [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.

  7. Drug

    Strontium ranelate

    go.drugbank.com/drugs/DB09267
    ApprovedWithdrawn

    Available for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an … It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis.

    Mixtures: STRODAY D3 2G/800 IU SAŞE , 28 SAŞE, FULLBONE D3 2 G/800 IU EFERVESAN TABLET, 30 ADET
  8. Drug

    Lubiprostone

    go.drugbank.com/drugs/DB01046
    ApprovedInvestigational

    Lubiprostone is a medication used in the management of idiopathic chronic constipation. … A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells.

  9. Drug

    Bifonazole

    go.drugbank.com/drugs/DB04794
    Approved

    Bifonazole is an azole antifungal drug.

    Mixtures: Canesten Bifonazol comp. - Salbe + Nagelset
  10. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718] … [A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell